Please use this identifier to cite or link to this item:
https://repository.monashhealth.org/monashhealthjspui/handle/1/52991| Title: | Publisher correction: Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b/4 trial. | Authors: | Harbeck N.;Ciruelos E.;Jerusalem G.;Muller V.;Niikura N.;Viale G.;Bartsch R.;Kurzeder C.;Higgins M.J.;Connolly R.M.;Baron-Hay S.;Gion M.;Guarneri V.;Bianchini G.;Wildiers H.;Escriva-de-Romani S.;Prahladan M.;Bridge H.;Kuptsova-Clarkson N.;Scotto N.;Verma S.;Lin N.U.;Anders C.;Hall P.;Zaman K.;Aebi S.;Rossi L.;Klint L.;Killander F.;Schiza A.;del Prado P.M.;Gonzalez C.H.;Flores E.G.;Sanchez C.R.;Lopez R.L.;Castan J.C.;Borrego M.R.;Marti M.P.L.;Gregori J.G.;Manich C.S.;Losada M.J.V.;Sousa A.R.;Cardoso F.;Simoes J.;Duchnowska R.;Jassem J.;Radecka B.;Nowecki Z.;Wysocki P.;Saetersdal A.;Engebraten O.;Pilskog M.;Houtsma D.;de Boer M.;Tomioka N.;Tsugawa K.;Tsurutani J.;Yamashita T.;Fotia V.;Biganzoli L.;Berardi R.;Caruso M.;De Laurentiis M.;McCaffrey J.;van Mackelenbergh M.;Marme F.;Grischke E.M.;Braun M.;Tio J.;Park-Simon T.-W.;Fasching P.;Untch M.;Tesch H.;Reinisch M.;Wimberger P.;Huovinen R.;Mattson J.;Tanner M.;Brix E.;Ronlev J.;Maraldo M.;Chia S.;Jerzak K.;De Cuypere E.;Collignon J.;Gombos A.;Murray N.;Clay T.;McCartney A. ;McCarthy N.;Yeo B. | Institution: | (Harbeck) Breast Center, Department of Gynecology and Obstetrics, Comprehensive Cancer Center Munich, LMU University Hospital, Munich, Germany (Ciruelos) Hospital Universitario 12 de Octubre, Madrid, Spain (Jerusalem) CHU Liege and Liege University, Liege, Belgium (Muller) University Medical Center Hamburg-Eppendorf, Hamburg, Germany (Niikura) Tokai University School of Medicine, Kanagawa, Japan (Viale) Department of Pathology and Laboratory Medicine, IEO European Institute of Oncology IRCCS, Milan, Italy (Bartsch) Division of Oncology, Department of Medicine 1, Medical University of Vienna, Vienna, Austria (Kurzeder) Breast Center, University Hospital Basel, Basel, Switzerland (Higgins) St. Vincent's University Hospital, UCD Cancer Trials Cluster, Dublin, Ireland (Connolly) Cancer Research @UCC, College of Medicine and Health, University College Cork, Cork, Ireland (Connolly) Cancer Trials Cork, CUH/UCC Cancer Center, Cork University Hospital, Cork, Ireland (Baron-Hay) Department of Medical Oncology, Royal North Shore Hospital, St Leonards, NSW, Australia (Gion) IOB-Madrid, Beata Maria Ana Hospital, Madrid, Spain (Gion) Department of Medical Oncology, Ramon y Cajal University Hospital, Madrid, Spain (Guarneri) Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy (Guarneri) Medical Oncology 2, Istituto Oncologico Veneto IRCCS, Padova, Italy (Bianchini) Department of Medical Oncology, IRCCS Ospedale San Raffaele, Milan, Italy (Bianchini) School of Medicine and Surgery, Vita-Salute San Raffaele University, Milan, Italy (Wildiers) Department of General Medical Oncology, University Hospitals Leuven, KU Leuven, Leuven, Belgium (Escriva-de-Romani) Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, Barcelona, Spain (Prahladan) Global Medical Affairs, Oncology R & D, AstraZeneca, Cambridge, United Kingdom (Bridge) Oncology Global Medical Affairs / Payer Biometrics, AstraZeneca, Macclesfield, United Kingdom (Kuptsova-Clarkson) Patient Safety, Oncology R & D, AstraZeneca, Gaithersburg, MD, United States (Scotto) Oncology Global Medical Affairs, AstraZeneca, Baar, Switzerland (Verma) Oncology Franchise, AstraZeneca, Gaithersburg, MD, United States (Lin) Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States (Yeo) Austin Health, Melbourne, Australia (McCarthy) ICON Cancer Care, Wesley, Australia (McCartney) Monash Medical Centre, Clayton, Australia (Clay) St John of God, Subiaco Hospital, Subiaco, Australia (Murray) GenesisCare, Adelaide, Australia (Gombos) Institut Jules Bordet, Brussels, Belgium (Collignon) CHU de Liege, Liege, Belgium (De Cuypere) AZ Sint-Jan Brugge-Oostende AV, Bruges, Belgium (Jerzak) Sunnybrook Health Sciences Centre, Toronto, Canada (Chia) BC Cancer Agency, Vancouver, Canada (Maraldo) Rigshospitalet, Copenhagen, Denmark (Ronlev) Odense University Hospital, Odense, Denmark (Brix) Herlev og Gentofte Hospital, Copenhagen, Denmark (Tanner) TAYS Sydankeskus Oy, Tampere, Finland (Mattson) HUS, Helsinki, Finland (Huovinen) Turku University Hospital, Turku, Finland (Wimberger) Universitatsklinikum Carl Gustav Carus der TU Dresden, Dresden, Germany (Reinisch) Kliniken Essen Mitte, Essen, Germany (Tesch) Centrum fur Hamatologie und Onkologie Bethanien, Frankfurt, Germany (Untch) Helios-Kliniken Berlin - Buch, Berlin, Germany (Fasching) Universitatsklinikum Erlangen, Erlangen, Germany (Park-Simon) Medizinische Hochschule Hannover, Hannover Medical School, Hannover, Germany (Tio) Universitatsklinikum Munster, Munster, Germany (Braun) Rotkreuzklinikum Munchen, Munich, Germany (Grischke) Universitatsklinikum Tubingen, Tubingen, Germany (Marme) Medizinische Fakultat Mannheim der Universitat Heidelberg, Heidelberg, Germany (van Mackelenbergh) Universitatsklinikum Schleswig-Holstein Campus Kiel, Kiel, Germany (McCaffrey) Mater Misericordiae University Hospital, Dublin, Ireland (De Laurentiis) Istituto Nazionale Tumori Fondazione Pascale IRCCS, Naples, Italy (Caruso) Humanitas Istituto Clinico Catanese, Catania, Italy (Berardi) AOU Ospedali Riuniti Umberto I - G.M. Lancisi - G. Salesi, Ancona, Italy (Biganzoli) Nuovo Ospedale di Prato, Prato, Italy (Fotia) A.O. Papa Giovanni XXIII, Bergamo, Italy (Yamashita) Kanagawa Cancer Center, Kanagawa, Japan (Tsurutani) Showa University Hospital, Shinagawa, Japan (Tsugawa) St. Marianna University Hospital, Kawasaki, Japan (Tomioka) National Hospital Organization Hokkaido Cancer Center, Sapporo, Hokkaido, Japan (de Boer) Maastricht University Medical Center, Maastricht, Netherlands (Houtsma) HAGA Ziekenhuis locatie Els Borst-Eilersplein, Hague, Netherlands (Pilskog) Helse Bergen HF Haukeland universitetssykehus, Bergen, Norway (Saetersdal, Engebraten) Oslo University Hospital, Oslo, Norway (Wysocki) Szpital Uniwersytecki w Krakowie, Krakow, Poland (Nowecki) Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie, Warsaw, Poland (Radecka) Opolskie Centrum Onkologii im. prof. T. Koszarowskiego, Opole, Poland (Jassem) Uniwersyteckie Centrum Kliniczne, Gdansk, Poland (Duchnowska) Wojskowy Instytut Medyczny, Warsaw, Poland (Simoes) Centro Hospitalar Universitario de Porto, Porto, Portugal (Cardoso) Fundacao Champalimaud, Lisbon, Portugal (Sousa) Centro Hospitalar Universitario Lisboa Norte, Lisbon, Portugal (Losada) Hospital Clinic Barcelona, Barcelona, Spain (Manich) Hospital Universitario Vall d'Hebron, Barcelona, Spain (Gregori) Fundacion Instituto Valenciano de Oncologia (IVO), Valencia, Spain (Marti) Hospital Universitario de la Princesa, Madrid, Spain (Borrego) Hospital Universitario Virgen del Rocio, Seville, Spain (Castan) Hospital Ruber Internacional, Madrid, Spain (Lopez) Complejo Hospitalario Universitario de Santiago (CHUS), Santiago, Spain (Sanchez) Hospital Clinico Universitario de Salamanca, Salamanca, Spain (Flores) Hospital Universitario Virgen de las Nieves, Granada, Spain (Gonzalez) Hospital Universitario Marques de Valdecilla, Santander, Spain (del Prado) Hospital Civil de Basurto, Bilbao, Spain (Schiza) Akademiska Sjukhuset Uppsala, Uppsala, Sweden (Killander) Skanes Universitetssjukhus, Lund, Sweden (Klint) Sahlgrenska Universitetssjukhuset, Goteborg, Sweden (Rossi) Ente Ospedaliero Cantonale, Bellinzona, Switzerland (Aebi) Luzerner Kantonsspital (LUKS) - Luzern, Luzern, Switzerland (Zaman) Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland (Hall) Western General Hospital, Edinburgh, United Kingdom (Anders) Duke University Medical Center, Durham, NC, United States |
Issue Date: | 19-Dec-2024 | Copyright year: | 2024 | Publisher: | Nature Research | Place of publication: | United States | Publication information: | Nature Medicine. 30(12) (pp 3780), 2024. Date of Publication: December 2024. | Journal: | Nature Medicine | Abstract: | Correction to: Nature Medicinehttps://doi.org/10.1038/s41591-024-03261-7, published online 13 September 2024. In the version of this article initially published, members of the DESTINY-Breast12 study group were not included by the journal in the full text. In Table 1, under the "Prior CNS therapies n (%)" section, seven rows have been added, in addition to the original CNS radiotherapy, WBRT and SRS rows. In Table 1 and in the Results: Patients section, "intracranial therapy" has been amended to "CNS radiotherapy," while the text "the type of intracranial radiotherapy was not always recorded by investigators, and only WBRT and SRS intracranial radiotherapy were reported" has been removed. All changes appear in the HTML and PDF versions of the article.Copyright © The Author(s) 2024. | DOI: | http://monash.idm.oclc.org/login?url=https://dx.doi.org/10.1038/s41591-024-03349-0 | PubMed URL: | 39653780 [https://www.ncbi.nlm.nih.gov/pubmed/?term=39653780] | URI: | https://repository.monashhealth.org/monashhealthjspui/handle/1/52991 | Type: | Erratum | Subjects: | radiotherapy | Type of Clinical Study or Trial: | Opinion, perspective or news |
| Appears in Collections: | Articles |
Show full item record
Items in Monash Health Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.